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The management of patients with symptomatic carotid
disease has been the subject of more scientific scrutiny than
any other vascular condition. In the 1980s/1990s, the Euro-
pean Carotid Surgery Trial (ECST) and the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)1,2
established the primacy of ‘evidence’ over ‘intuitive
reasoning’ and these landmark trials laid down quality
standards for reporting outcomes. These included; (i) the
need to publish standardised and independently audited
procedural risks and (ii) three/five year rates of stroke free
survival (including peri-operative strokes and deaths) using
‘intention to treat’ analyses. These basic principles remain
the cornerstone underpinning international guidelines of
practice since ECST and NASCET reported in 1991.1,2
However this concept of ‘one size fits all’ often sits
uncomfortably in real world practice, especially now that
carotid artery stenting (CAS) has emerged as a less invasive
alternative to carotid endarterectomy (CEA). No fewer than
eleven randomised trials comparing CAS with CEA have been
undertaken in recently symptomatic patients, with the most
influential (largely because of their large size and contem-
porary nature) being EVA-3S, SPACE, ICSS and CREST. In this
edition of the European Journal of Vascular and Endovas-
cular Surgery, the Carotid Stenting Trialists Collaboration
(CSTC) present an overview of their individual patient meta-
analysis of 3433 recently symptomatic patients who werety for Vascular Surgery. Publisherandomised within EVA-3S, SPACE or ICSS.3 Using the ECST/
NASCET format for reporting procedural risks, the main
conclusion was that CAS was associated with a significantly
higher risk of procedural death/stroke than CEA (8.9% vs
5.8%; Absolute Risk Reduction (ARR) Z 3.2%; Hazard Ratio
1.53 (95% CI 1.2e1.95)).4
Moreover, because of the large number of patients
included within the meta-analysis, it was also possible to
perform meaningful subgroup analyses. Here, the key
finding was that CAS patients aged <70 years encountered
virtually the same risks as patients undergoing CEA (5.8% vs
5.7%, Hazard Ratio 1.0 (95%CI 0.68e1.47)). Conversely, CAS
patients aged >70 years faced a significantly higher risk of
stroke/death than those undergoing CEA (12.0% vs 5.9%);
ARR Z 6.1%; Hazard Ratio 2.04 (95%CI 1.48e2.82)). In
addition, while there was no difference in the rate of peri-
operative death/disabling stroke in patients aged <70
years, stented patients aged >70 years incurred a statisti-
cally significant doubling of the risk of death or disabling
stroke in the early post-intervention period, compared with
patients randomised to CEA (OR 1.8 (95%CI 1.2e2.7),
p Z 0.0071). One of the other highly topical issues in
carotid practice is the trend towards intervening as soon as
possible after the patient suffers their index event. While
the CSTC were unable to report on outcomes in patients
treated within two weeks of their index symptom, they
were able to show that patients who underwent stenting
within two weeks of their most recent clinical event were
almost three times more likely to die or suffer a procedurald by Elsevier Ltd. All rights reserved.
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days (OR 2.7 (95%CI 1.4e5.5).4
The CSTC4 concluded that; “stenting for symptomatic
carotid stenosis should be avoided in older patients (aged
70 years), but that CAS might be as safe as endarterec-
tomy in younger patients”. To most observers this will be
a reasonable observation, but (as will be seen) it does
become hard to reconcile this interpretation of the
evidence with the opinions expressed by the American
Heart Association (AHA) in their 2011 guidelines for
managing patients with TIA or stroke.5
Not included in the CSTC meta-analysis were the results
from CREST (the North American randomised trial6). CREST
recruited neurologically symptomatic and asymptomatic
patients, but when 30-day outcomes were analysed in
symptomatic patients (ie eligible for randomisation within
CSTC trials), CAS was (once again) associatedwith a doubling
of the risk of peri-operative stroke/death (6.0% vs 3.2%,
Hazard Ratio 1.9 (95%CI 1.1e3.2%)). CREST did, however,
show that procedural risks following CAS were broadly
equivalent to CEA in patients aged<70 years, while CAS was
significantly inferior to CEA in patients aged >70 years5 ie
corroborating the CSTC findings.4 Accordingly, if one simply
uses the standard definition of procedural risk adopted in
NASCET and ECST (ie death/any stroke), any overview of the
CSTC and CREST data would have to conclude that CEA was
superior to CAS. For that reason, an editorial (written by
Australian Neurologists) which accompanied CREST in the
New England Journal of Medicine concluded that CEA should
remain the ‘gold-standard’ in symptomatic patients7 echoing
the opinions of French Neurologists in an editorial in the
Lancet following publication of both the CSTC meta-analysis
and a review of the CREST data.8
However; on virtually the same day that the CSTC pub-
lished its meta-analysis, the AHA released its 2011 recom-
mendations for the treatment of patients presentingwith TIA
or minor stroke.5 In a very comprehensive document
(extending to 50 pages), the AHA indicated that they had
analysed the ‘available data’ and concluded that there was
now Class I, Level B evidence that; “CAS was indicated as an
alternative to CEA for symptomatic patients at average or
low risk of complications associated with endovascular
interventionwhen the diameter of the lumen of the internal
carotid artery was reduced by>70% by non-invasive imaging
or >50% by catheter angiography”. How can the CTSC and
AHA conclusions appear so divergent? More importantly;
were they setting out to answer the same questions?
The first observation tomake is that while it was perfectly
understandable for the AHA to have no access to the CTSC
meta-analysis during its literature review, there was no
excuse for omitting any reference (whatsoever) to ICSS,
whilst finding itself able to include CREST in its review of
evidence. This is despite the fact that ICSS released its
results at least one year before CREST and remains the
largest randomised trial in symptomatic patients. The
second observation is that the format for reporting outcomes
was substantially different within CREST (compared to ICSS
and CSTC) and this newer format has been adopted by the
AHA in its deliberations. Rather than stratifying outcomes for
mode of presentation, CREST chose to combine outcome
data for symptomatic and asymptomatic patients.6 In
addition; interpretation of these combined data wereconfounded by the inclusion of ‘chemical’ myocardial
infarction (MI) within a composite endpoint of 30-day death/
stroke/MI. As a consequence, it was the combined 30-day
death/stroke/MI rates for symptomatic and asymptomatic
patients (5.2% after CAS vs 4.5% after CEA, p Z 0.386) that
were influential in leading the AHA to justify their Level I,
Class B recommendation for CAS in symptomatic patients.5
So was it reasonable for the AHA to have ‘changed the
question’ in order to secure a different answer to the
question posed in the CSTC meta-analysis? The inclusion of
‘chemical’ MI within a composite endpoint (ie giving it
equivalent status to death or procedural stroke) has
become a highly controversial issue and has polarised
opinion. This is primarily because, in CREST, CEA was
associated with a doubling of the risk of procedural MI
(which was not observed in either ICSS or CSTC), leading to
the loss of statistical significance when procedural risks
were analysed in the ‘traditional’ way. However; if
‘chemical’ MI does confer a significantly poorer prognosis in
the long term (eg reduced survival), should this not be
considered important when discussing management options
with our patients? If true; the answer has to be ‘yes’; it is
reasonable to have changed the question.
However, despite having introduced this new format for
interpreting procedural risk/benefit analyses in its 2011
recommendations, the AHA then failed to address other
important questions, solely because it completely ignored
the ICSS trial. In an MRI substudy, ICSS observed that CAS
was associated with a five fold increase in new ischaemic
lesions on DWI MRI, compared with CEA (50% vs 17%; Hazard
Ratio 5.2 (95%CI 2.8e9.8); p < 0.0001). When repeated at
4e6 weeks post-intervention, CAS was still associated with
a sixfold increase in persisting new ischaemic lesions on
FLAIR MRI imaging (33% vs 8%; Hazard Ratio 5.9 (95%CI
2.3e15.6); p Z 0.003).9 Interestingly, these findings were
almost identical to the results of a systematic review of
new ischaemic lesions in non-randomised patients under-
going CEA and CAS.10 No-one (as yet) knows the clinical
relevance of these lesions (high quality studies have not
been done), but if they were to predispose the patient to an
increased risk of dementia or cognitive impairment, this
finding could prove to be of equivalent clinical relevance to
‘chemical’ MI.
Accordingly; it is probably true that where contempo-
rary procedural risks are concerned, we should increase the
number of questions that have to be asked when inter-
preting these (or any future) trial results and not just
adhere to the reporting standards introduced by NASCET
and ECST. However, one cannot simply pick and choose
which questions you wish to ask and then ignore the rest. To
that end; we would propose that the following key ques-
tions need to be addressed in any future AHA or European
guidelines. These would include; (i) which is the safer
intervention (CAS or CEA) for treating patients in the
hyperacute period after onset of symptoms (ie the first
7e14 days), (ii) does rapid treatment in the hyperacute
period influence any recommendation regarding the
optimal intervention (CEA or CAS) in patients who are >70
or <70 years of age? (iii) are the majority of cranial nerve
injuries after CEA ‘benign’ and short lived, and what
proportion should be considered the equivalent of having
suffered a stroke? (iv) do patients with new (or persisting)
152 Editorialischaemic lesions on MRI after CEA or CAS face an increased
risk of late cognitive impairment? (v) will alternative
cerebral protection devices (such as flow reversal) reduce
the risk of new cerebral ischaemic lesions after CAS? (vi) if
a patient suffers a peri-operative ‘chemical’ MI after CEA or
CAS, is this associated with poorer long-term survival? and
(vi) if CAS is to be increasingly adopted into routine clinical
practice, how will practitioners complete their ‘learning
curve’ (currently thought to be about 50 procedures11)
without harming patients?
Several of these ‘new’ questions (the significance of
cranial nerve injury after CEA, the significance of chemical
MI after CEA and the significance of new ischaemic lesions
after CAS) remain highly emotive subjects and need to be
addressed by scientific evaluation rather than inter-disci-
plinary speculation. To that end, CREST has already indi-
cated that it intends to report on the clinical importance of
the first two questions, leaving the third for others to
undertake. It is crucial, however, that the relevance of new
ischaemic lesions (after both CEA and CAS) is evaluated
properly. The issue about generalisability and the learning
curve is also relevant. The importance of this is highlighted
by the latest National Inpatient Sample from the United
States (56,564 CAS procedures and 482,394 CEAs), which
showed that in ‘non-high risk’ symptomatic patients, CAS
was associated with significantly higher rates of procedural
death (5.3% vs 1.0%, p < 0.001), stroke (7.5% vs 4.2%,
p < 0.0001) and death/stroke (11.8% vs 4.9%, p < 0.0001).12
These morbidity and mortality rates are twice those
observed in CREST and suggest that (as was noted during
the landmark CEA trials) procedural risks may be much
higher in ‘routine clinical practice’ than within the confines
of a randomised trial which exercised rigorous interven-
tionist/surgeon selection criteria and scrutiny.
While these more ‘emotive’ questions are being
addressed, the other key issue remains the importance of
starting ‘best medical therapy’ and offering CEA or CAS as
soon as possible after onset of symptoms. Some surgeons
and interventionists may still not be comfortable with the
current worldwide drive towards treating patients with TIA
or minor stroke within 7e14 days of suffering their index
event (perhaps within 48e72 h in the future13), but this
practice is likely to be of more practical benefit to the
patient (because rapid intervention leads to more strokes
prevented in the long term) than any debate about the
significance of new cerebral ischaemic lesions, chemical
MIs or cranial nerve injuries.
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